Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents

Chun Yi Lu, Pei Lan Shao, Luan Yin Chang, Yhu Chering Huang, Cheng Hsun Chiu, Yu Chia Hsieh, Tzou Yien Lin, Li Min Huang

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The 2009 pandemic influenza A (H1N1) has caused significant morbidity and mortality around the world. Safety and immunogenicity studies of 2009 pandemic influenza A (H1N1) virus in children and adolescents are limited. In this prospective, open-label study, 2 doses of a monovalent, unadjuvanted, inactivated, split-virus 2009 pandemic influenza virus A (H1N1) vaccine (AdimFlu-S) were administered to 183 healthy children and adolescents aged 1-17 years. Adverse reactions were assessed, and hemagglutination inhibition antibody titers were determined. Three weeks after the first dose, 36.2% of children aged 1-2 years, 52.5% of children aged 3-5 years, 56.7% of children aged 6-9 years, and 90.3% of adolescents aged 10-17 years generated protective antibodies. A second vaccination given 3 weeks later induced protective antibodies in 89.4% of all age groups. No severe adverse effects were found 6 weeks after vaccination.

Original languageEnglish
Pages (from-to)5864-5870
Number of pages7
JournalVaccine
Volume28
Issue number36
DOIs
Publication statusPublished - Aug 2010
Externally publishedYes

Fingerprint

Influenza A virus
Pandemics
pandemic
Vaccines
immune response
vaccines
Safety
influenza
antibodies
Antibodies
Vaccination
vaccination
H1N1 Subtype Influenza A Virus
Hemagglutination
hemagglutination
dosage
Human Influenza
morbidity
Age Groups
adverse effects

Keywords

  • Children
  • H1N1
  • Vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this

Lu, C. Y., Shao, P. L., Chang, L. Y., Huang, Y. C., Chiu, C. H., Hsieh, Y. C., ... Huang, L. M. (2010). Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. Vaccine, 28(36), 5864-5870. https://doi.org/10.1016/j.vaccine.2010.06.059

Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. / Lu, Chun Yi; Shao, Pei Lan; Chang, Luan Yin; Huang, Yhu Chering; Chiu, Cheng Hsun; Hsieh, Yu Chia; Lin, Tzou Yien; Huang, Li Min.

In: Vaccine, Vol. 28, No. 36, 08.2010, p. 5864-5870.

Research output: Contribution to journalArticle

Lu, Chun Yi ; Shao, Pei Lan ; Chang, Luan Yin ; Huang, Yhu Chering ; Chiu, Cheng Hsun ; Hsieh, Yu Chia ; Lin, Tzou Yien ; Huang, Li Min. / Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. In: Vaccine. 2010 ; Vol. 28, No. 36. pp. 5864-5870.
@article{b653109bd0db472a88e1d16b3c29f856,
title = "Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents",
abstract = "The 2009 pandemic influenza A (H1N1) has caused significant morbidity and mortality around the world. Safety and immunogenicity studies of 2009 pandemic influenza A (H1N1) virus in children and adolescents are limited. In this prospective, open-label study, 2 doses of a monovalent, unadjuvanted, inactivated, split-virus 2009 pandemic influenza virus A (H1N1) vaccine (AdimFlu-S) were administered to 183 healthy children and adolescents aged 1-17 years. Adverse reactions were assessed, and hemagglutination inhibition antibody titers were determined. Three weeks after the first dose, 36.2{\%} of children aged 1-2 years, 52.5{\%} of children aged 3-5 years, 56.7{\%} of children aged 6-9 years, and 90.3{\%} of adolescents aged 10-17 years generated protective antibodies. A second vaccination given 3 weeks later induced protective antibodies in 89.4{\%} of all age groups. No severe adverse effects were found 6 weeks after vaccination.",
keywords = "Children, H1N1, Vaccine",
author = "Lu, {Chun Yi} and Shao, {Pei Lan} and Chang, {Luan Yin} and Huang, {Yhu Chering} and Chiu, {Cheng Hsun} and Hsieh, {Yu Chia} and Lin, {Tzou Yien} and Huang, {Li Min}",
year = "2010",
month = "8",
doi = "10.1016/j.vaccine.2010.06.059",
language = "English",
volume = "28",
pages = "5864--5870",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "36",

}

TY - JOUR

T1 - Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents

AU - Lu, Chun Yi

AU - Shao, Pei Lan

AU - Chang, Luan Yin

AU - Huang, Yhu Chering

AU - Chiu, Cheng Hsun

AU - Hsieh, Yu Chia

AU - Lin, Tzou Yien

AU - Huang, Li Min

PY - 2010/8

Y1 - 2010/8

N2 - The 2009 pandemic influenza A (H1N1) has caused significant morbidity and mortality around the world. Safety and immunogenicity studies of 2009 pandemic influenza A (H1N1) virus in children and adolescents are limited. In this prospective, open-label study, 2 doses of a monovalent, unadjuvanted, inactivated, split-virus 2009 pandemic influenza virus A (H1N1) vaccine (AdimFlu-S) were administered to 183 healthy children and adolescents aged 1-17 years. Adverse reactions were assessed, and hemagglutination inhibition antibody titers were determined. Three weeks after the first dose, 36.2% of children aged 1-2 years, 52.5% of children aged 3-5 years, 56.7% of children aged 6-9 years, and 90.3% of adolescents aged 10-17 years generated protective antibodies. A second vaccination given 3 weeks later induced protective antibodies in 89.4% of all age groups. No severe adverse effects were found 6 weeks after vaccination.

AB - The 2009 pandemic influenza A (H1N1) has caused significant morbidity and mortality around the world. Safety and immunogenicity studies of 2009 pandemic influenza A (H1N1) virus in children and adolescents are limited. In this prospective, open-label study, 2 doses of a monovalent, unadjuvanted, inactivated, split-virus 2009 pandemic influenza virus A (H1N1) vaccine (AdimFlu-S) were administered to 183 healthy children and adolescents aged 1-17 years. Adverse reactions were assessed, and hemagglutination inhibition antibody titers were determined. Three weeks after the first dose, 36.2% of children aged 1-2 years, 52.5% of children aged 3-5 years, 56.7% of children aged 6-9 years, and 90.3% of adolescents aged 10-17 years generated protective antibodies. A second vaccination given 3 weeks later induced protective antibodies in 89.4% of all age groups. No severe adverse effects were found 6 weeks after vaccination.

KW - Children

KW - H1N1

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=77955551077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955551077&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2010.06.059

DO - 10.1016/j.vaccine.2010.06.059

M3 - Article

C2 - 20600484

AN - SCOPUS:77955551077

VL - 28

SP - 5864

EP - 5870

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 36

ER -